Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.

China-based metabolic disease therapy developer Sciwind Biosciences has raised $37m in series B funding from investors including Legend Capital, the venture capital firm spun out of conglomerate Legend Holdings. Life sciences-focused investment firm Lyfe Capital led the round, investing with VC firm Haibang Venture Capital, which was identified as an existing backer. Founded in 2017,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.